补气活血利水方联合腹水浓缩回输治疗乙型肝炎肝硬化顽固性腹水

目的：评价补气活血利水方药联合自体腹水超滤浓缩回输治疗肝硬化顽固性腹水的临床疗效。方法将90例乙肝肝硬化合并顽固性腹水患者随机分为观察组与对照组，每组45例，均接受常规治疗和腹水浓缩回输治疗，观察组患者加用补气活血利水方药。结果观察组和对照组的总有效率分别为88.9%和64.4%（P 〈0.05）。治疗后，观察组较对照组的丙氨酸氨基转移酶（44.40±13.10）U/L vs.（56.90±15.50）U/L]、白蛋白（33.04±3.13）g/L vs.（30.94±3.52）g/L]、总胆红素（39.04±8.13）μmol/L vs.（52.94±9.52）μmol/L]、直接胆红素（16.04±4.13）μmol/L vs.（19.94±5.52）μmol/L]、胆碱酯酶（3043.55±141.23）mmol/L vs.（2894.42±169.52）mmol/L]明显改善，差异有统计学意义（P 〈0.05）；肾功能的差异无统计学意义（P 〉0.05）。组内比较，治疗后各项指标均明显好于治疗前（P 〈0.05）。发热、肝性脑病、血压下降等不良反应发生率也无明显差异（P 〉0.05）。结论补气活血利水方联合腹水浓缩回输治疗可以明显提高肝硬化顽固性腹水的临床疗效。

Buqi huoxue lishui decoction combined with ascites reinfusion in the treatment of refractory ascites in hepatitis B liver cirrhosis patients

Objective To evaluate the clinical efficacy of buqi huoxue lishui decoction combined with reinfusion of concentrated ascites in the treatment of refractory cirrhosis ascites. Methods Ninety cases of hepatitis B assaciated liver cirrhosis with refractory ascites were randomly divided into the observation group and the control group, both received con-ventional therapy and ascites reinfusion treatment, while the observation group was treated with the combination of buqi huoxue lishui decoction. Results The total response rate of the observation group and the control group was 88.9% and 64.4%（P 〈 0.05）. After treatment, the liver function tests in the observation group were better than those of the control group, ALT（44.40±13.10）U/L vs. （56.90±15.50）U/L], ALB（33.04±3.13）g/L vs. （30.94±3.52）g/L], T-BIL（39.04±8.13）μmol/L vs. （52.94±9.52）μmol/L]. D-BIL （16.04±4.13）μmol/L vs. （19.94±5.52）μmol/L], CHE （3 043.55±141.23） mmol/L vs. （2 894.42±169.52）mmol/L], P 〈 0.05. The liver function tests after therapy in each group were better than those of the pre-therapy （P〈0.05 ）. While there were no significant differences in renal function and adverse reactions （fever, hepatic encephalopathy, blood pressure decline） between the two groups after therapy （P 〉0.05）. Conclusion Buqi huoxue lishui decoction combined with reinfusion of concentrated ascites can significantly improve the clinical efficacy of liver cirrhosis with refractory ascites.